Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 28Cisplatin 18Nivolumab 14Cyclophosphamide 14Carboplatin 14Paclitaxel 12Radiotherapy 10Radiation 10Radiotherapy, Intensity-Modulated 9Magnetic Resonance Spectroscopy 9Doxorubicin 9Docetaxel 9Cytarabine 8Bevacizumab 8Radiosurgery 7Leucovorin 7Gemcitabine 7Fluorouracil 7Vincristine 6Prednisone 6Pemetrexed 6Lenalidomide 6Irinotecan 6Etoposide 6Dexamethasone 6venetoclax 5tislelizumab 5fludarabine 5enzalutamide 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bupropion × 30 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡